αCP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant αCP-4a, is underexpressed in lung cancer

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4171-4179

  Pio, Ruben ^a,b   Zudaire, Isabel ^a   Pino, Irene ^a   Castaño, Zafira ^a   Zabalegui, Natalia ^a   Vicent, Silvestre ^a   Garcia Amigot, Fermin ^a   Odero, Maria D ^a   Lozano, Maria D ^a   Garcia Foncillas, Jesus ^a   Calasanz, Maria J ^a   Montuenga, Luis M ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHACP 4 PROTEIN; ALPHACP 4A PROTEIN; KI 67 ANTIGEN; PROTEIN; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; BRONCHIOLE; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CHROMOSOME 3P; CHROMOSOME DELETION; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PCBP4 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; BIOPSY; CELL DIVISION; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENE DELETION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RNA-BINDING PROTEINS;

EID: 3042569690     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2982     Document Type: Article

References (41)

1. Sundaresan V, Ganly P, Hasleton P, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 1992;7:1989-97.
2. Hung J, Kishimoto Y, Sugio K, et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. J Am Med Assoc 1995;273: 558-63.
3. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366-73.
4. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelo-typing of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60:1949-60.
5. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000;60:6116-33.
6. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
7. Tomizawa Y, Sekido Y, Kondo M, et al. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci USA 2001;98:13954-9.
8. Sutherland LC, Lerman M, Williams GT, Miller BA. LUCA-15 suppresses CD95-mediated apoptosis in Jurkat T cells. Oncogene 2001;20:2713-9.
9. Makeyev AV, Liebhaber SA. The poly(C)-binding proteins: a multiplicity of functions and a search for mechanisms. RNA 2002;8:265-78.
10. Makeyev AV, Liebhaber SA. Identification of two novel mammalian genes establishes a subfamily of KH-domain RNA-binding proteins. Genomics 2000; 67:301-16.
11. Zhu J, Chen X. MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)-M. Mol Cell Biol 2000;20:5602-18.
12. Chkheidze AN, Liebhaber SA. A novel set of nuclear localization signals determine distributions of the alphaCP RNA-binding proteins. Mol Cell Biol 2003;23: 8405-15.
13. Davis LG, Kuehl WM, Battey JM. Basic methods in Molecular Biology, 2 edition. Norwalk, CT: Appleton & Lange, 1994:322-28.
14. Watsuji T, Okamoto Y, Emi N, Katsuoka Y, Hagiwara M. Controlled gene expression with a reverse tetracycline-regulated retroviral vector (RTRV) system. Biochem Biophys Res Commun 1997;234:769-73.
15. Daly MC, Xiang RH, Buchhagen D, et al. A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. Oncogene 1993;8:1721-9.
16. Kok K, van den Berg A, Veldhuis PM, van der Veen AY, et al. A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. Cancer Res 1994;54:4183-7.
17. Wei MH, Latif F, Bader S, et al. Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res 1996;56:1487-92.
18. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSFIA in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
19. Brambilla E, Constantin B, Drabkin H, Roche J. Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration. Am J Pathol 2000;156:939-50.
20. Ji L, Nishizaki M, Gao B, et al. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 2002;62:2715-20.
21. Kondo M, Ji L, Kamibayashi C, et al. Overexpression of candidate tumor suppressor gene FUSI isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 2001;20:6258-62.
22. Timmer T, Terpstra P, van den Berg A, et al. A comparison of genomic structures and expression patterns of two closely related flanking genes in a critical lung cancer region at 3p21.3. Eur J Hum Genet 1999;7:478-86.
23. Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci USA 1975;72:5116-20.
24. Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, Arnold A. Cyclin D1 (PRAD1) alternative transcript b: full-length cDNA cloning and expression in breast cancers. Cancer Lett 1997;113:123-30.
25. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996;2:912-7.
26. Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
27. Oh Y, Proctor ML, Fan YH, et al. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene 1998;17:1141-8.
28. Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 1998;29:910-4.
29. Stickeler E, Kittrell F, Medina D, Berget SM. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 1999;18: 3574-82.
30. Pino I, Pio R, Toledo G, et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 2003;41:131-43.
31. Perrotti D, Bonatti S, Trotta R, et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J 1998;17:4442-55.
32. Yang L, Embree LJ, Hickstein DD. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol Cell Biol 2000;20: 3345-54.
33. Kovar H, Jug G, Hattinger C, et al. The EWS protein is dispensable for Ewing tumor growth. Cancer Res 2001;61:5992-7.
34. Iervolino A, Santilli G, Trotta R, et al. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and Bcr/Abl leukemogenesis. Mol Cell Biol 2002;22:2255-66.
35. Gouble A, Grazide S, Meggetto F, Mercier P, Delsol G, Morello D. A new player in oncogenesis: AUF1/hnRNP D overexpression leads to tumorigenesis in transgenic mice. Cancer Res 2002;62:1489-95.
36. Maeda T, Hiranuma H, Jikko A. Differential expression of the splicing regulatory factor genes during two-step chemical transformation in a BALB/3T3-derived cell line, MT-5. Carcinogenesis 1999;20:2341-4.
37. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
38. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, Castle VP. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995;55:2576-82.
39. Xerri L, Parc P, Brousset P, et al. Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol 1996;92:900-6.
40. Gazzaniga P, Gradilone A, Silvestri I, et al. Variable levels of bcl-2, bcl-x and bax mRNA in bladder cancer progression. Oncol Rep 1998;5:901-4.
41. Miyamoto Y, Hosotani R, Wada M, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 1999;56:73-82.